Suppliers / Alpex Pharma

Alpex Pharma

Switzerland 64 employees Updated 9 July 2026

Alpex Pharma is a contract manufacturer based in Switzerland. It appears in 17 regulatory filings across 5 regulators, without an active US DMF or CEP on file. Its filings concentrate with EMA, URPL (PL) and NPRA (MY). Its GMP standing is certified by US FDA and FDA (GH). Its most recent recorded inspection, by US FDA, closed on 14 December 2023 as VAI.

0
active US DMFs
0
valid CEPs
2
registered plants 1 with an FDA FEI number
17
filings across 5 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
1 of 1 confirmed
Inspections
3 of 3 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026.

Inspection history

  • 14 December 2023 VAI US FDA
  • 21 August 2015 NAI US FDA
  • 24 February 2011 NAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
Switzerland, Switzerland 3004311700
Mezzovico-Vira, Switzerland Not on file

Filings and GMP by regulator

Regulator Filings GMP certificates
EMA 7 None
URPL (PL) 5 None
NPRA (MY) 2 None
ANSM (FR) 2 None
UZPHARM (UZ) 1 None
US FDA None 1
FDA (GH) None 1

Comparing suppliers?

Choose your molecules and target markets. Alpex Pharma comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • The most recent inspection outcome was VAI, on 14 December 2023.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates